Navigation Links
Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device
Date:12/16/2009

(Aarhus, Denmark, December 14, 2009) Unisense FertiliTech A/S has received a further 1.6 million Euro in capital funding to scale up production and support of the EmbryoScope™ Embryo Monitoring System in order to meet the rapidly growing demand for this promising new technology. The capital was invested by LD Pensions and Unisense A/S that continue to own each about 50% of the company.

Aarhus, Denmark (PRWEB) December 16, 2009 -- Unisense FertiliTech A/S has received a further 1.6 million Euro in capital funding to scale up production and support of the EmbryoScope™ Embryo Monitoring System in order to meet the rapidly growing demand for this promising new technology. The capital was invested by LD Pensions and Unisense A/S that continue to own each about 50% of the company.

During IVF treatment, multiple oocytes are removed from the patient and fertilized in-vitro. The resulting fertilized eggs are allowed to develop for a period of 2 to 5 days, before the embryologist must select the best potential embryo or embryos to transfer back to the patient. Ideally, a single embryo resulting in a single pregnancy is optimal as multiple pregnancies present risks to both maternal and fetal health.

A major challenge for the embryologist is determining which embryos have the best potential to create a single healthy baby. The EmbryoScope® Embryo Monitoring System allows uninterrupted time-lapse observation of embryo development in a stable controlled incubation environment. Embryo quality parameters can be assessed and reviewed without the potentially damaging effects of removing the embryo from a stable controlled environment.

CEO Jens Gundersen says they are encouraged with the overwhelming response to the initial sales launch of the instrument, and that with the additional capital, FertiliTech will be able to scale up production to meet the demands of the rapidly expanding interest for the EmbryoScope® Embryo monitoring system.

Unisense FertiliTech A/S is a Danish company which was founded in 2003, as a daughter company of Unisense A/S. The company develops and manufactures instruments and analysis solutions to facilitate in-vitro Fertilization. The company is highly research oriented and is currently involved in various international research projects involving improved embryo selection and analysis, embryo respiration and stem cell research.

Contact Person:
Francesca Bahr
Sales and Marketing Manager
Unisense FertiliTech A/S
Phone Number +45 89449525
Mobile Phone: +45 40255538

Jens K. Gundersen
CEO
+45 21601675

Email Address fab (at) fertilitech (dot) com
Website URL http://www.fertilitech.com

###

Read the full story at http://www.prweb.com/releases/2009/12/prweb3339374.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Increased distance to physician associated with thicker skin cancer at diagnosis
2. Methamphetamine study suggests increased risk for HIV transmission
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Minorities more likely to have sleep durations associated with increased mortality
5. Teens who see more smoking in movies may have increased risk of becoming established smokers
6. Study shows adverse drug events reported to the FDA have significantly increased
7. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
8. Maternal depression and controlling behavior associated with increased stress response in infants
9. BioProcessors Launches SimCell(TM) Services to Meet Increased Customer Demand
10. Both short and long sleep is associated with increased mortality
11. New Study Shows Lower Costs, Increased Consumer Engagement in Account-Based Health Plans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
(Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... 05, 2016 , ... At its annual meeting held last week, the American ... National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We ... Chambers , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... CENTENNIAL, Colo. , Feb. 5, 2016  As ... about health. The multitude of recommended screenings and tests ... healthy aging a priority. However, for the majority of ... of proactive health planning. For the 37.5 million American ... time like the present to make hearing health a ...
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology: